Microcap Ledger XBiotech Inc. $XBIT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Austin, TX
- Fiscal year end
- December 31
- Shares outstanding
- 30,487,731 [10-Q 2026-08-13]
What the company doesAI summary of filing
XBiotech Inc. is a clinical-stage biopharmaceutical company that discovers and develops monoclonal antibodies derived from human donors for treating inflammatory, infectious, and oncologic diseases. The company generates revenue from manufacturing services and clinical trial operations for pharmaceutical partners, and previously received $750 million in cash from the 2019 sale of an IL-1a-targeting antibody therapeutic. XBiotech is currently advancing multiple product candidates in clinical development, including Natrunix for pancreatic cancer and rheumatoid arthritis, and Hutrukin for stroke, alongside earlier-stage infectious disease programs targeting conditions such as MRSA, C. difficile, shingles, and influenza. [10-K 2026-03-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$12.23M | −$13.48M | $109.53M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$45.54M | −$39.92M | $125.55M | [DEF 14A 2026-10-02] |
| FY ended Dec 2024 | — | −$38.53M | −$30.96M | $172.68M | [DEF 14A 2026-10-02] |
- Quarterly cash burn
- −$6.74M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 30,483,481 | [10-Q 2024-11-13] |
| 2025-03-18 | 30,487,731 | [10-K/A 2025-04-29] |
| 2025-05-14 | 30,487,731 | [10-Q 2025-05-14] |
| 2025-08-13 | 30,487,731 | [10-Q 2025-08-13] |
| 2025-11-12 | 30,487,731 | [10-Q 2025-11-12] |
| 2026-03-13 | 30,487,731 | [10-K/A 2026-04-29] |
| 2026-05-14 | 30,487,731 | [10-Q 2026-05-14] |
| 2026-08-13 | 30,487,731 | [10-Q 2026-08-13] |
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-04-07. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-04-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-07] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-02 | DEF 14A | Proxy statement |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-04-29 | 10-K/A | Amended report |
| 2026-03-13 | 10-K | Annual report |
| 2026-01-23 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-01-23 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2025-12-09 | 8-K | Director or officer change |
| 2025-11-12 | 10-Q | Quarterly report |
| 2025-10-15 | 8-K | Director or officer change |
Alerts for $XBIT
Email me when XBiotech Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.